EPS Exceeds Expectations, Revenues Lag
Viveve Medical (NASDAQ:VIVE) Third Quarter 2022 Results
Main financial results
Revenue: $1.68 million (up 4.2% compared to Q3 2021).
Net loss: $6.32 million (loss reduced by 10% compared to Q3 2021).
Loss of $0.59 per share (improving from the loss of $0.67 in 3Q 2021).
All figures shown in the table above are for the 12 month period (TTM)
Viveve Medical EPS Exceeds Expectations, Revenues Fall Short
Revenue missed analysts’ estimates by 1.2%. Earnings per share (EPS) exceeded analysts’ estimates by 11%.
Going forward, revenue is expected to grow 57% per year on average over the next 3 years, compared to a growth forecast of 7.4% for the US medical device industry.
Performance of the American medical equipment industry.
Shares of the company are down 9.7% from a week ago.
You should always think about the risks. Concrete example, we spotted 2 warning signs for Viveve Medical you should be aware of, and 1 of them is significant.
Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at) Simplywallst.com.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.
Join a Paid User Research Session
You will receive a $30 Amazon Gift Card for 1 hour of your time while helping us create better investment tools for individual investors like you. register here